Jump to content

Merck KGaA 's Matuzumab


Recommended Posts

FRANKFURT (Thomson Financial) - Merck KGaA said its division Merck Serono's Phase II trial of Matuzumab to treat metastatic colorectal cancer (mCRC) did not meet its predefined endpoint, adding it is 'reconsidering' further development of the drug.

Matuzumab is being co-developed and co-commercialised jointly by Merck Serono and Takeda.

'Both companies share the view that the study results in mCRC do not meet expectations,' Merck said.

However the two companies will continue to study the drug in other tumours, including non-small cell lung cancer

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.